Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Pfizer, Inc.

Equities

PFE

US7170811035

Real-time Estimate Cboe BZX
Other stock markets
 01:13:22 2024-04-25 pm EDT 		5-day change 1st Jan Change
25.42 USD -3.25% Intraday chart for Pfizer, Inc. +0.14% -11.69%
07:00pm GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines MT
06:40pm GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines
MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines
MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement
MT
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
RE
Bristol Myers posts quarterly loss, revenue rises 5%
RE
Scholz promises support for pharma sector in Germany as Merck invests
RE
Pfizer Keeps Q2 Dividend at $0.42 a Share, Payable June 14 to Holders of Record May 10
MT
Pfizer Declares Second-Quarter 2024 Dividend
BU
Pfizer Inc. Declares Second-Quarter 2024 Dividend, Payable on June 14, 2024
CI
Pfizer : Political Action Committee (PAC) Report
PU
Second Circuit Rules That Associational Standing For A Preliminary Injunction Requires Identifying At Least One Injured Member By Name
AQ
Big pharma giants in English High Court for global Covid dispute
AQ
Edwards Lifesciences Corporation: The story continues
Our Logo
European Commission Approves Pfizer's EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options
AQ
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
RE
European Commission approves novel antibiotic
AQ
Pfizer: new Emblaveo antibiotic approved in the EU
CF
Pfizer's Emblaveo Receives European Commission Marketing Approval
MT
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
BU
European Commission Approves Pfizer?s Emblaveo® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.